趋化因子CXCR7/CXCL11/CXCL12生物轴在狼疮肾炎患者外周血中表达研究

Abstract
Figure/Table
References (27)
Related Citation (15)

Download: PDF (503 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the expression level and significance of CXC chemokine receptor 7 (CXCR7) and CXC-type chemokine ligand (CXCL) 11 and CXCL12 in peripheral blood of lupus nephritis (LN). Methods Forty patients with systemic lupus erythematosus (SLE) treated in the Department of Rheumatology, Xuzhou Central Hospital(“our hospital” for short) from October 2018 to October 2020 were selected as the study subjects. SLE patients were divided into the LN group (n 24 cases) and the non-LN group (16 cases). Twenty healthy subjects in the control group were examined in our hospital during the same period. Flow cytometry was used to detect the expression of CD3+CXCR7+T lymphocytes and CD19+CXCR7+B lymphocytes in peripheral blood of the three groups. The concentrations of CXCL11 and CXCL12 in serum were detected by enzyme-linked immunosorbent assay. Results The expression percentage of CD3+CXCR7+T lymphocyte and CD19+CXCR7+B lymphocyte in peripheral blood and the expression levels of CXCL11 and CXCL12 in serum of LN group were higher than those of non-LN group and healthy control group, the differences were statistically significant (P ＜ 0.05). The expression levels of CD3+CXCR7+T lymphocytes, CD19+CXCR7+B lymphocytes, CXCL11 and CXCL12 in the non-LN group were higher than those of healthy control group, the differences were statistically significant(P ＜ 0.05). The expression levels of CD19+CXCR7+ lymphocytes, CD3+CXCR7+ lymphocytes, CXCL11, and CXCL12 in peripheral blood of patients with LN were positively correlated with the quantification of 24 h urinary protein (P ＜ 0.001). Conclusion The high expression levels of CXCR7, CXCL11, and CXCL12 are related to the pathogenesis of LN patients. The CXCR7/CXCL11/CXCL12 may play an important role in the pathogenesis of LN.

Key words： Lupus nephritis CXC chemokine receptor 7 Cxc-type chemokine ligand 11 Cxc-type chemokine ligand 12

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZU Beibei1 MA Qianqian2 RAO Yongmei2 LI Meirong2 LIU Lin2 ZHANG Li3▲

Cite this article:

ZU Beibei1 MA Qianqian2 RAO Yongmei2 LI Meirong2 LIU Lin2 ZHANG Li3▲. Expression of CXCR7, CXCL11 and CXCL12 biological axis in the peripheral blood of patients with lupus nephritis[J]. 中国医药导报, 2022, 19(17): 139-142.

URL:

https://www.yiyaodaobao.com.cn/EN/ OR https://www.yiyaodaobao.com.cn/EN/Y2022/V19/I17/139

[1] Arriens C，Wren JD，Munroe ME，et al. Systemic lupus erythematosus biomarkers： the challenging quest [J]. Rhe-umatology （Oxford），2017，56（suppl）：i32-i45.
[2] Aringer M，Petri M. New classification criteria for systemic lupus erythematosus [J]. Curr Opin Rheumatol，2020，32（6）：590-596.
[3] Laufer JM，Legler DF. Beyond migration-chemokines in lymphocyte priming，differentiation，and modulating effector functions [J]. Leukoc Biol，2018，104（2）：301-312.
[4] Lounsbury N. Advances in CXCR7 Modulators [J]. Pharmaceuticals （Basel），2020，13（2）：33-48.
[5] Nguyen HT，Reyes-Alcaraz A，Yong HJ，et al. CXCR7：a β-arrestin-biased receptor that potentiates cell migration and recruits β-arrestin2 exclusively through Gβγ subunits and GRK2 [J]. Cell Biosci，2020，10（1）：134-153.
[6] Tawalbeh SM，Marin W，Morgan GA，et al. Serum protein biomarkers for juvenile dermatomyositis： a pilot study[J]. BMC Rheumatol，2020，1（4）：52-67.
[7] Puchert M，Koch C，Zieger K，et al. Identification of CXCL11 as part of chemokine network controlling skeletal muscle development [J]. Cell Tissue Res，2021，384（2）：499-511.
[8] Elia G. MIG in psoriatic arthritis [J]. Clin Ter，2018，169（6）：e297-e302.
[9] Crescioli C，Corinaldesi C，Riccieri V，et al. Association of circulating CXCL10 and CXCL11 with systemic sclerosis [J]. Ann Rheum Dis，2018，77（12）：1845-1846.
[10] Watanabe K，Penfold ME，Matsuda A，et al. Pathogenic role of CXCR7 in rheumatoid arthritis [J]. Arthritis Rheum，2010，62（11）：3211-3220.
[11] Padern G，Duflos C，Ferreira R，et al. Identification of a Novel Serum Proteomic Signature for Primary Sj?觟gren’s Syndrome [J]. Front Immunol，2021，12（2）：1-12.
[12] Yang P，Tan J，Yuan Z，et al. Expression profile of cytokines and chemokines in osteoarthritis patients： Proinflammatory roles for CXCL8 and CXCL11 to chondrocytes [J]. Int Immunopharmacol，2016，40（11）：16-23.
[13] Bombardier C，Gladman DD，Urowitz MB，et al. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE [J]. Arthritis Rheum，1992，35（6）：630-640.
[14] Petri M，Orbai AM，Alarcón GS，et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus [J]. Arthritis Rheum，2012，64（8）：2677-2686.
[15] Vacchini A，Locati M，Borroni EM. Overview and potential unifying themes of the atypical chemokine receptor family [J]. J Leukoc Biol，2016，99（6）：883-892.
[16] Hughes CE，Nibbs RJB. A guide to chemokines and their receptors [J]. FEBS J，2018，285（16）：2944-2971.
[17] Laufer JM，Legler DF. Beyond migration-chemokines in lymphocyte priming，differentiation，and modulating effector functions [J]. Leukoc Biol，2018，104（2）：301-312.
[18] Ulvmar MH，Hub E，Rot A. Atypical chemokine receptors [J]. Exp Cell Res，2011，317（5）：556-568.
[19] Steen A，Larsen O，Thiele S，et al. Biased and g protein-independent signaling of chemokine receptors [J]. Front Immunol，2014，5（277）：1-7.
[20] Wang C，Chen W，Shen J. CXCR7 Targeting and Its Major Disease Relevance [J]. Front Pharmacol，2018，21（9）：641-652.
[21] Nibbs RJ，Graham GJ. Immune regulation by atypical chemokine receptors [J]. Nat Rev Immunol，2013，13（11）：815-829.
[22] Huynh C，Dingemanse J，Meyer Zu，et al. Relevance of the CXCR4/CXCR7-CXCL12 axis and its effect in pathophysiological conditions [J]. Pharmacol Res，2020，161（11）：1-11.
[23] Puchert M，Obst J，Koch C，et al. CXCL11 promotes tumor progression by the biased use of the chemokine receptors CXCR3 and CXCR7 [J]. Cytokine，2020，125：154809.
[24] Wedemeyer MJ，Mahn SA，Getschman AE，et al. The chemokine X-factor： Structure-function analysis of the CXC motif at CXCR4 and ACKR3 [J]. J Biol Chem，2020，295（40）：13927-13939.
[25] Koch C，Engele J. Functions of the CXCL12 Receptor ACKR3/CXCR7-What Has Been Perceived and What Has Been Overlooked [J]. Mol Pharmacol，2020，98（5）：577-585.
[26] 祖蓓蓓，刘琳，饶咏梅，等.系统性红斑狼疮患者外周血中趋化因子基质细胞衍生因子-1α及其受体CXC趋化因子受体4的检测及其临床意义[J].中华风湿病学杂志，2013，17（12）：828-832.
[27] 祖蓓蓓，饶咏梅，李美荣，等.狼疮肾炎患者外周血中趋化因子受体CXCR4及其配体SDF-1α的表达研究[J].临床与实验医学杂志，2013，13（23）：1884-1887.